Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug;30(7-8):1695-1729.
doi: 10.1007/s10495-025-02123-y. Epub 2025 May 15.

Tumor heterogeneity and resistance in glioblastoma: the role of stem cells

Nikita Ghosh  1 , Debarpan Chatterjee  2 , Aparna Datta  3
Affiliations
Review

Tumor heterogeneity and resistance in glioblastoma: the role of stem cells

Nikita Ghosh et al. Apoptosis. 2025 Aug.

Abstract

Glioblastoma multiforme (GBM) is one of the most aggressive and treatment-resistant brain tumor, characterized by its heterogeneity and the presence of glioblastoma stem cells (GSCs). GSCs are a subpopulation of cells within the tumor that possess self-renewal and differentiation capabilities, contributing to tumor initiation, progression, and recurrence. This review explores the unique biological properties of GSCs, including their molecular markers, signalling pathways, and interactions with the tumor microenvironment. We discuss the mechanisms by which GSCs evade conventional therapies, such as enhanced DNA repair and metabolic plasticity, which complicate treatment outcomes. Furthermore, we highlight recent advancements in identifying novel biomarkers and therapeutic targets that may improve the efficacy of treatments aimed at GSCs. The potential of targeted therapies, including immunotherapy and combination strategies, is also examined to overcome the challenges posed by GSCs. Ultimately, a deeper understanding of GSC biology is essential for developing personalized treatment approaches that can enhance patient outcomes in glioblastoma.

Keywords: Biomarkers; Combination strategies; Glioblastoma multiforme; Glioblastoma stem cells; Immunotherapy; Treatment resistant brain tumor.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

Similar articles

See all similar articles

References

    1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820 - PubMed
    1. Kleihues P, Ohgaki H (1999) Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1(1):44–51 - PubMed - PMC
    1. Korbecki J, Kojder K, Grochans S, Cybulska AM, Simi D (2022) Epidemiology of glioblastoma multiforme – literature review
    1. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y et al (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the united States in 2006–2010. Neuro Oncol. 15(SUPPL 2).
    1. Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ et al (2012) Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107(1):207–212 - PubMed

LinkOut - more resources